安田 浩之 (ヤスダ ヒロユキ)

Yasuda, Hiroyuki

写真a

所属(所属キャンパス)

医学部 内科学教室(呼吸器) (信濃町)

職名

准教授

外部リンク

経歴 【 表示 / 非表示

  • 2001年04月
    -
    2005年03月

    慶應義塾大学医学部内科学教室

  • 2005年04月
    -
    2010年12月

    慶應義塾大学医学部内科学(呼吸器)

  • 2011年01月
    -
    2012年03月

    Beth Israel Deaconess Medical Center, Harvard Medical School

  • 2012年04月
    -
    継続中

    慶應義塾大学医学部内科学(呼吸器)

学歴 【 表示 / 非表示

  • 2001年

    慶応義塾大学, 医学部

    卒業

学位 【 表示 / 非表示

  • 医学博士, 慶應義塾大学, 論文

 

研究分野 【 表示 / 非表示

  • ライフサイエンス / 分子生物学 (腫瘍生物学)

  • ライフサイエンス / 細胞生物学 (細胞生物学)

  • ライフサイエンス / 呼吸器内科学 (肺癌)

研究キーワード 【 表示 / 非表示

  • オルガノイド

  • トランスレーショナル研究

  • バイオバンク

  • 細胞生物学

  • 肺癌

全件表示 >>

 

論文 【 表示 / 非表示

  • A 70-Year-Old Woman With Long-Term Nonresolving Pneumonia.

    Tomiyasu S, Kabata H, Emoto K, Azekawa S, Maeda C, Masai K, Yasuda H, Fukunaga K

    Chest 161 ( 4 ) e219 - e223 2022年04月

    ISSN  0012-3692

  • Longitudinal Assessment of Prognostic Understanding in Patients with Advanced Lung Cancer and Its Association with Their Psychological Distress

    Arai D., Sato T., Nakachi I., Fujisawa D., Takeuchi M., Sato Y., Kawada I., Yasuda H., Ikemura S., Terai H., Nukaga S., Inoue T., Nakamura M., Oyamada Y., Terashima T., Sayama K., Saito F., Sakamaki F., Naoki K., Fukunaga K., Soejima K.

    Oncologist (Oncologist)  26 ( 12 ) e2265 - e2273 2021年12月

    ISSN  10837159

     概要を見る

    Background: Accurate prognostic understanding in patients with advanced cancer is essential for shared decision making; however, patients may experience psychological burden through knowing the incurable nature of advanced cancer. It has been unclear how their prognostic understanding fluctuates and whether accurate prognostic understanding is associated with psychological distress from the time of diagnosis over time. Materials and Methods: We longitudinally investigated prognostic understanding in 225 patients with newly diagnosed advanced lung cancer at 16 hospitals in Japan until 24 months after diagnosis. We examined associated factors with being consistently accurate in prognostic understanding, especially focusing on its association with psychological well-being. Results: The proportion of patients with an inaccurate prognostic understanding remained approximately 20% over time with the presence of patients with inconsistent understanding. Patients with consistently accurate prognostic understanding showed a significantly lower Emotional Well-Being subscale score at both 3 and 6 months after diagnosis (p =.010 and p =.014, respectively). In multivariate analyses, being consistently accurate in prognostic understanding was significantly associated with female gender and higher lung cancer–specific symptom burden at 3 months (p =.008 and p =.005, respectively) and lower emotional well-being at 6 months (p =.006). Conclusion: Although substantial proportions of patients with advanced lung cancer had inaccurate prognostic understanding from the time of diagnosis over time, patients with consistently accurate prognostic understanding experienced greater psychological burden. Our findings highlight the importance of continuous psychological care and support for patients who understand their severe prognosis accurately. Implications for Practice: This study demonstrated that approximately 20% of patients with advanced lung cancer had an inaccurate understanding about their prognosis, not only at the time of diagnosis but also at the later time points. Being consistently accurate in prognostic understanding was significantly associated with elevated levels of psychological distress. Although accurate prognostic understanding is essential for decision making for treatment and advance care planning, health care providers should be aware of psychological burdens in patients that accept their severe prognosis accurately. Appropriate care and support for such patients are warranted from diagnosis over time.

  • A phase I/II study of osimertinib in EGFR exon 20 insertion mutation-positive non-small cell lung cancer

    Yasuda H., Ichihara E., Sakakibara-Konishi J., Zenke Y., Takeuchi S., Morise M., Hotta K., Sato M., Matsumoto S., Tanimoto A., Matsuzawa R., Kiura K., Takashima Y., Yano S., Koyama J., Fukushima T., Hamamoto J., Terai H., Ikemura S., Takemura R., Goto K., Soejima K.

    Lung Cancer (Lung Cancer)  162   140 - 146 2021年12月

    ISSN  01695002

     概要を見る

    Objectives: Several preclinical data proposed a potential efficacy of osimertinib, a third-generation EGFR tyrosine kinase inhibitor, for EGFR exon 20 insertion (EGFR ex20ins)-positive non-small cell lung cancer (NSCLC). However, reported case series and a retrospective study proposed controversial efficacy. The efficacy of osimertinib in EGFR ex20ins-positive NSCLC have not been well evaluated in prospective clinical trials. In this study, we performed a prospective, single-arm, multi-center, open-label, non-randomized phase I/II study to evaluate efficacy of osimertinib for EGFR ex20ins-positive NSCLC. Materials and methods: From August 2018 to January 2020, 14 NSCLC patients with EGFR ex20ins were enrolled, of whom 2 were excluded because they did not meet the inclusion criteria. Efficacy and safety of 80 mg osimertinib were evaluated. In addition, we performed a translational exploratory study to clarify the association of mutation type-specific drug sensitivity, osimertinib pharmacokinetic data, and clinical efficacy. Results: Of the evaluated patients, none experienced objective response, 7 experienced stable disease (58.3%), and 5 experienced disease progression (41.7%). The median progression free survival (PFS) was 3.8 months, and the median overall survival was 15.8 months. Interestingly, the exploratory study demonstrated statistically significant positive correlation between plasma osimertinib concentration/in vitro IC50 ratio and PFS (R = 0.9912, P = 0.0001), highlighting the mutation type-specific concentration-dependent efficacy of osimertinib for EGFR ex20ins-positive NSCLC. Conclusions: Regular dose, 80 mg/day, of osimertinib has limited clinical activity in NSCLC patients with EGFR ex20ins. The translational study proposed the potential efficacy of higher dose osimertinib in a subgroup of EGFR ex20ins-positive NSCLC.

  • Comprehensive and long-term surveys of COVID-19 sequelae in Japan, an ambidirectional multicentre cohort study: study protocol.

    Nakagawara K, Namkoong H, Terai H, Masaki K, Tanosaki T, Shimamoto K, Lee H, Tanaka H, Okamori S, Kabata H, Chubachi S, Ikemura S, Kamata H, Yasuda H, Kawada I, Ishii M, Ishibashi Y, Harada S, Fujita T, Ito D, Bun S, Tabuchi H, Kanzaki S, Shimizu E, Fukuda K, Yamagami J, Kobayashi K, Hirano T, Inoue T, Kagyo J, Shiomi T, Ohgino K, Sayama K, Otsuka K, Miyao N, Odani T, Oyamada Y, Masuzawa K, Nakayama S, Suzuki Y, Baba R, Nakachi I, Kuwahara N, Ishiguro T, Mashimo S, Minematsu N, Ueda S, Manabe T, Funatsu Y, Koh H, Yoshiyama T, Saito F, Ishioka K, Takahashi S, Nakamura M, Goto A, Harada N, Kusaka Y, Nakano Y, Nishio K, Tateno H, Edahiro R, Takeda Y, Kumanogoh A, Kodama N, Okamoto M, Umeda A, Hagimura K, Sato T, Miyazaki N, Takemura R, Sato Y, Takebayashi T, Nakahara J, Mimura M, Ogawa K, Shimmura S, Negishi K, Tsubota K, Amagai M, Goto R, Ibuka Y, Hasegawa N, Kitagawa Y, Kanai T, Fukunaga K

    BMJ open respiratory research 8 ( 1 )  2021年11月

  • Nasal delivery of single-domain antibody improves symptoms of SARS-CoV-2 infection in an animal model

    Haga K., Takai-Todaka R., Matsumura Y., Song C., Takano T., Tojo T., Nagami A., Ishida Y., Masaki H., Tsuchiya M., Ebisudani T., Sugimoto S., Sato T., Yasuda H., Fukunaga K., Sawada A., Nemoto N., Murata K., Morimoto T., Katayama K.

    PLoS Pathogens (PLoS Pathogens)  17 ( 10 ) e1009542 2021年10月

    ISSN  15537366

     概要を見る

    The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that causes the disease COVID-19 can lead to serious symptoms, such as severe pneumonia, in the elderly and those with underlying medical conditions. While vaccines are now available, they do not work for everyone and therapeutic drugs are still needed, particularly for treating life-threatening conditions. Here, we showed nasal delivery of a new, unmodified camelid single-domain antibody (VHH), termed K-874A, effectively inhibited SARS-CoV-2 titers in infected lungs of Syrian hamsters without causing weight loss and cytokine induction. In vitro studies demonstrated that K-874A neutralized SARS-CoV-2 in both VeroE6/TMPRSS2 and human lung-derived alveolar organoid cells. Unlike other drug candidates, K-874A blocks viral membrane fusion rather than viral attachment. Cryo-electron microscopy revealed K-874A bound between the receptor binding domain and N-terminal domain of the virus S protein. Further, infected cells treated with K-874A produced fewer virus progeny that were less infective. We propose that direct administration of K-874A to the lung could be a new treatment for preventing the reinfection of amplified virus in COVID-19 patients.

全件表示 >>

KOARA(リポジトリ)収録論文等 【 表示 / 非表示

全件表示 >>

総説・解説等 【 表示 / 非表示

競争的研究費の研究課題 【 表示 / 非表示

  • 酸素を用いた癌治療法の開発

    2024年06月
    -
    2027年03月

    安田 浩之, 挑戦的研究(開拓), 補助金,  研究代表者

  • 肺癌オルガノイドライブラリーを用いた肺癌シグナル経路異常の解明

    2021年04月
    -
    2024年03月

    文部科学省・日本学術振興会, 科学研究費助成事業, 安田 浩之, 基盤研究(B), 補助金,  研究代表者

  • 肺癌オルガノイドライブラリー統合解析による癌の不均一性の解明と新規治療標的同定

    2020年04月
    -
    2022年03月

    日本医療研究開発機構(AMED), 次世代がん医療創生研究事業, 安田浩之, 研究代表者

  • 肺癌オルガノイドを用いた治療後期肺癌の悪性度の本態解明

    2019年04月
    -
    2022年03月

    日本医療研究開発機構(AMED), 革新的がん医療実用化研究事業, 安田浩之, 未設定

  • 肺癌オルガノイドライブラリーを用いたprecision medicineの確立と新規治療標的の同定

    2018年11月
    -
    2020年03月

    日本医療研究開発機構(AMED), 次世代がん医療創生研究事業, 安田浩之, 未設定

全件表示 >>

受賞 【 表示 / 非表示

  • 武田科学振興財団研究助成金(医学系研究継続助成)

    2019年

    受賞区分: その他

  • 研究奨励賞 日本肺癌学会

    2018年

    受賞区分: 国内学会・会議・シンポジウム等の賞

  • 武田科学振興財団研究助成金(医学系研究)

    2016年

    受賞区分: その他

  • 日本肺癌学会 若手奨励賞

    2015年

  • 第55回 日本呼吸器学会 学会奨励賞

    2015年

全件表示 >>

 

担当授業科目 【 表示 / 非表示

  • 薬理学

    2024年度

  • 内科学(呼吸器)講義

    2024年度

  • 呼吸器内科学臨床実習

    2024年度

  • 内科学(呼吸器)臨床実習

    2024年度

  • 薬理学

    2023年度

全件表示 >>

 

所属学協会 【 表示 / 非表示

  • 日本癌治療学会, 

    2021年03月
    -
    継続中
  • 日本癌学会, 

    2020年10月
    -
    継続中
  • International Association for the Study of Lung Cancer, 

    2018年10月
    -
    継続中
  • 日本臨床腫瘍学会, 

    2007年04月
    -
    継続中
  • American Association for Cancer Research, 

    2005年10月
    -
    継続中

全件表示 >>